| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Mitogen-activated protein kinases (MAPKs) were extensively studied in cancer-derived cell lines; however, studies in non-transformed human cells are scarce. In the current paper, we studied the effect of SB203580, a pharmacological inhibitor of p38 MAPK, on activation and inhibition of p38 MAPK transduction partway in primary human hepatocytes (in vitro model of differentiated cells) in comparison with several tumor cell lines (proliferating non-differentiated in vitro model). In addition, we analyzed the effect of SB203580 on extracellular-regulated protein kinase (ERK) and c-jun-N-terminal kinase (JNK) pathways both in primary human hepatocytes and tumor cell lines employing primary antibodies detecting phosphorylated kinases. We show that SB203580 activates ERK and JNK in primary cultures of human hepatocytes. The levels of ERK-P(Thr202/Tyr204), JNK-P(Thr183/Tyr185) and c-Jun-P(Ser63/73), a target down-stream protein of JNK, were increased by SB203580. In contrast, SB203580 activated ERK b
- Mitogen-activated protein kinases (MAPKs) were extensively studied in cancer-derived cell lines; however, studies in non-transformed human cells are scarce. In the current paper, we studied the effect of SB203580, a pharmacological inhibitor of p38 MAPK, on activation and inhibition of p38 MAPK transduction partway in primary human hepatocytes (in vitro model of differentiated cells) in comparison with several tumor cell lines (proliferating non-differentiated in vitro model). In addition, we analyzed the effect of SB203580 on extracellular-regulated protein kinase (ERK) and c-jun-N-terminal kinase (JNK) pathways both in primary human hepatocytes and tumor cell lines employing primary antibodies detecting phosphorylated kinases. We show that SB203580 activates ERK and JNK in primary cultures of human hepatocytes. The levels of ERK-P(Thr202/Tyr204), JNK-P(Thr183/Tyr185) and c-Jun-P(Ser63/73), a target down-stream protein of JNK, were increased by SB203580. In contrast, SB203580 activated ERK b (en)
- Mitogeny-aktivované protein kinasy (MAPKs) byly intenzivně studovány v nádorových liniích, ale studie v netransformovaných lidských buňkách jsou vzácné. Zde jsme studovali účinek SB203580, farmakologického inhibitoru p38 MAPK, na aktivaci a inhibici p38 signální dráhy v primárních lidských hepatocytech (in vitro model diferencovaných buněk) ve srovnání s několika nádorovými buněčnými liniemi (in vitro model proliferujících a nediferencovaných buněk). Analyzovali jsme účinek SB203580 na extracellulárně-regulovanou protein kinasu (ERK) a c-jun-N-terminální kinasu (JNK) v primárních lidských hepatocytech I v nádorových buněčných liniích za využití primárních protilátek proti fosforylovaným kinasam. Ukazujeme, že SB203580 aktivuje ERK a JNK v primárních kulturách lidských hepatocytů. Hladiny ERK-P(Thr202/Tyr204), JNK-P(Thr183/Tyr185) a c-Jun-P(Ser63/73), cílového down-stream proteinu JNK, byly zvýšeny účinkem SB203580. Na druhou stranu, SB203580 aktivoval ERK ale ne JNK v lidských nádorových liniích HepG2 (cs)
|
| Title
| - SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes.
- SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. (en)
- SB203580, farmakologický inhibitor signální dráhy p38 kinasy aktivuje ERK a JNK MAP kinasy v primárních kulturách lidských hepatocytů. (cs)
|
| skos:prefLabel
| - SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes.
- SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. (en)
- SB203580, farmakologický inhibitor signální dráhy p38 kinasy aktivuje ERK a JNK MAP kinasy v primárních kulturách lidských hepatocytů. (cs)
|
| skos:notation
| - RIV/61989592:15310/08:00005337!RIV09-MSM-15310___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA303/07/0128), P(GP305/08/P089), S, Z(MSM6198959216)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15310/08:00005337
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Human hepatocyte; p38 MAPK kinase; Extracellular-regulated kinase ERK; c-Jun-N-terminal kinase; SB203580; Cross-talk (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - European Journal of Pharmacology
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Bednář, Petr
- Dvořák, Zdeněk
- Papoušková, Barbora
- Pávek, Petr
- Ulrichová, Jitka
- Vrzal, Radim
- Anzenbacherová, Eva
- Jančová, Petra
- Henklová, Pavla
- Maurel, Patrik
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)